Primal Therapies, Inc.

For over a decade, Primal Therapies, Inc. has been reshaping the landscape of oral and systemic health. Disrupting the industry as a biotech trailblazer, Primal Therapies’ experts swiftly innovate cutting-edge microbiome modulatory products using their patented technology known as Selective Microbial Metabolism Regulation Technology (SMMRT®). Collaborating with leaders across various industries, with a primary focus on healthcare, novel solutions are crafted utilizing small molecules (such as prebiotics, postbiotics, and antimicrobials) to selectively target microbes. This approach maximizes outcomes in the realm of biofilm-related oral and systemic diseases. Whether addressing antimicrobial-resistant biofilms, dysbiotic microbiomes, or sluggish biofermentation reactors, SMMRT technology proves versatile in halting the growth of undesirable microbes, altering the microbial metabolome, or enhancing fermentation yields. To learn more about this transformative technology, visit www.primaltherapies.com.